CoChat

Antifungal persistence: Clinical relevance and mechanisms

Open access
Wang, Rui, Lv, Jingnan, Chen, Liang, Zhao, Yanan, Du, Hong · 2025 · PLoS pathogens

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index; 92 of the 155 sources its claims cite were checked for support.

Abstract

Review defining antifungal persistence as survival of a subpopulation at high drug concentrations, distinct from tolerance and resistance, and emphasizing its phenotypic, reversible nature.

Overview

CoChat Summary

TL;DR

This review defines antifungal persistence as a non-heritable, population-level phenomenon in which a small subpopulation of dormant fungal cells survives high-dose antifungals without increased MIC, distinct from resistance, tolerance, and heteroresistance. It synthesizes detection methods, mechanisms, and clinical/treatment evidence, concluding that direct clinical outcome evidence and mechanistic understanding remain limited.

Key findings

  • Antifungal persistence is heterogeneous: generally <<1% of the population survives, time-kill assays show similar MDK99 to susceptible strains but substantially higher MDK99.99, and MIC does not increase; unlike resistance, it is non-heritable.
  • Mechanisms include a dormant low-metabolism state (downregulated glycolysis, TCA cycle, and PPP; reduced ATP; upregulated glyoxylate cycle and gluconeogenesis), stress responses (SODs, Ahp1, ergothioneine, Hsp12, Hsp90 family), and adhesion/biofilm initiation; AmB-tolerant persisters are absent in some Candida spp. biofilms, and dormancy alone is insufficient.
  • Clinical relevance: in vivo models show higher fungal burden in persistent A. fumigatus isolates after voriconazole in Galleria mellonella and higher fungal burden plus echinocandin-resistance mutation rate in N. glabratus mouse infection; long-term C. albicans oral carriers had higher persistence, and persistent candidemia isolates showed high azole tolerance.
  • Treatment: persisters are recalcitrant to multiple antifungals, but cited agents including sertraline, Lavandula angustifolia essential oil, polymethacrylates, VT-1161, and gH625-M can eradicate persisters in specific models; a SOD inhibitor reduced the persister fraction by 18-fold.

Methods

  • Narrative review; no primary experiments. It synthesizes definitions, distinctions from resistance/tolerance/heteroresistance, detection methods, molecular mechanisms, and in vivo/clinical observations.
  • Evidence base includes cited studies in Candida spp., Cryptococcus, Aspergillus, and other fungi, using in vitro assays, animal models, and clinical observations.
  • Main analysis is qualitative synthesis with figures and a treatment table; no systematic review search strategy is stated.

Limitations

  • The paper states that conclusive evidence directly tying fungal persistence to clinical outcomes such as recurrent infections is still lacking, and that mechanisms remain poorly defined and multifactorial.
  • The paper notes that AmB-tolerant persisters are absent in biofilms of some Candida spp., dormancy alone is insufficient, energy-metabolism studies are predominantly in biofilms and may not apply to planktonic cells, and adhesion research is limited to biofilm-associated genes, lacks specific pathways, and covers limited species.
  • Evident from the text: as a narrative review, it reports no primary data or systematic search; some mechanisms are presented as likely rather than proven in persisters, as indicated by the figure legends distinguishing solid and dashed lines.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1013456

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Persistence versus resistance, tolerance, and heteroresistance. First of all, the progeny of persisters will still divide into persistence subpopulations and non-persistence subpopulations, while resistance and tolerance can be stably inherited to their progeny. In antifungal susceptibility testing, the MIC of persistence and tolerance do not increase, while resistance and the resistant population of heteroresistance show a high level of MIC. In time-kill assay, antifungal persistence is characterized by biphasic-killing curve, which represents the similar MDK99 as a susceptible strain. However, MDK99.99 is substantially higher for a persistent strain than the MDK99.99 for a susceptible strain. Concentrations and timescales are chosen for illustration purposes only. Abbreviations: MIC, minimal inhibitory concentration; MDK99, minimum duration of treatment that kills 99% of the population; MDK99.99, minimum duration of treatment that kills 99.99% of the population.
Fig 1 Persistence versus resistance, tolerance, and heteroresistance. First of all, the progeny of persisters will still divide into persistence subpopulations and non-persistence subpopulations, while resistance and tolerance can be stably inherited to their progeny. In antifungal susceptibility testing, the MIC of persistence and tolerance do not increase, while resistance and the resistant population of heteroresistance show a high level of MIC. In time-kill assay, antifungal persistence is characterized by biphasic-killing curve, which represents the similar MDK99 as a susceptible strain. However, MDK99.99 is substantially higher for a persistent strain than the MDK99.99 for a susceptible strain. Concentrations and timescales are chosen for illustration purposes only. Abbreviations: MIC, minimal inhibitory concentration; MDK99, minimum duration of treatment that kills 99% of the population; MDK99.99, minimum duration of treatment that kills 99.99% of the population.CC BY · PubMed Central
Fig 2 Dormant state promotes antifungal persistence. Energy-generating pathways are down-regulated in persisters, including glycolysis, TCA cycle and PPP. It has been proven that reduced ATP level is directly related to the formation of persistence. Meanwhile, energy-storage pathways are up-regulated in persisters, including glyoxylate cycle and gluconeogenesis. In general, protein biosynthesis is down-regulated in persisters, including translation regulator TMA19, elongation factor EF-Tu, and TORC1 involved in Ras pathway. Ergosterol biosynthesis is down-regulated in AmB-tolerant perisisters with decreased AmB targets, and it is up-regulated in voriconazole-tolerant Aspergillus fumigatus persisters with improved cell membrane integrity. Solid lines: proven in persisters. Dashed lines: likely to occur in persisters. Blue color: down-regulated. Red color: up-regulated. Abbreviations: TCA cycle, tricarboxylic acid cycle. PPP, pentose phosphate pathway. ATP, adenosine triphosphate. TORC1, target of rapamycin complex 1.
Fig 2 Dormant state promotes antifungal persistence. Energy-generating pathways are down-regulated in persisters, including glycolysis, TCA cycle and PPP. It has been proven that reduced ATP level is directly related to the formation of persistence. Meanwhile, energy-storage pathways are up-regulated in persisters, including glyoxylate cycle and gluconeogenesis. In general, protein biosynthesis is down-regulated in persisters, including translation regulator TMA19, elongation factor EF-Tu, and TORC1 involved in Ras pathway. Ergosterol biosynthesis is down-regulated in AmB-tolerant perisisters with decreased AmB targets, and it is up-regulated in voriconazole-tolerant Aspergillus fumigatus persisters with improved cell membrane integrity. Solid lines: proven in persisters. Dashed lines: likely to occur in persisters. Blue color: down-regulated. Red color: up-regulated. Abbreviations: TCA cycle, tricarboxylic acid cycle. PPP, pentose phosphate pathway. ATP, adenosine triphosphate. TORC1, target of rapamycin complex 1.CC BY · PubMed Central
Fig 3 Stress response pathways protect antifungal persisters to survive. When challenged with ROS, persisters up-regulate antioxidant activities, including SODs, ergothioneine, and Ahp1. HDA and Ras-cAMP pathway are involved in the activity against apoptosis, which protect persisters to survive. Moreover, HSP family may participate in some general stress response of persisters, such as Hsp12 in DNA damage. Solid lines: proven in persisters. Dashed lines: likely to occur in persisters. Abbreviations: SODs, superoxide dismutases. Ahp1, alkyl hydroperoxide reductase 1. HDA, histone deacetylase. HSP, heat shock protein. DSBs, double-strand breaks.
Fig 3 Stress response pathways protect antifungal persisters to survive. When challenged with ROS, persisters up-regulate antioxidant activities, including SODs, ergothioneine, and Ahp1. HDA and Ras-cAMP pathway are involved in the activity against apoptosis, which protect persisters to survive. Moreover, HSP family may participate in some general stress response of persisters, such as Hsp12 in DNA damage. Solid lines: proven in persisters. Dashed lines: likely to occur in persisters. Abbreviations: SODs, superoxide dismutases. Ahp1, alkyl hydroperoxide reductase 1. HDA, histone deacetylase. HSP, heat shock protein. DSBs, double-strand breaks.CC BY · PubMed Central

Verification

Claims the paper makes

66 Valid · 4 Not valid · 38 Not checked · 22 Own results and interpretations

75 more claims · 38 with their cited sources checked

Create a free account to see all 130 claims and to verify the 6 references still open.

See all claims — free account
  • It may state two separate claims as one. 42
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Research works printed but not linked: 2

  1. A Brauner, 2016, Distinguishing between resistance, tolerance and persistence to antibiotic treatment, Nat Rev Microbiol, 14, 320, 10.1038/nrmicro.2016.34 · DOI · Paper page
  2. K Lewis, 2010, Persister cells, Annu Rev Microbiol, 64, 357, 10.1146/annurev.micro.112408.134306 · DOI · Paper page

Cited by

See all 12

Metadata

Authors
Wang, R., Lv, J., Chen, L., Zhao, Y., & Du, H.
Affiliations
  • Second Affiliated Hospital of Soochow University (CN)
  • University at Buffalo, State University of New York (US)
Corresponding author
Du, Hong
Venue
PLoS pathogens
Published
2025-09-11
Volume
21
Issue
9
Pages
e1013456
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W4414154061
Cited by
12
References
80
Citations by year
2026: 12
FWCI
2.09
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Key Research and Development Project of Jiangsu Provincial Science and Technology Department (BE2023704)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Keywords
antifungal resistance, antifungal tolerance, chronic fungal infection, recurrent fungal infection
MeSH terms
Clinical Relevance, Animals, Antifungal Agents, Fungi, Humans, Mycoses, Drug Resistance, Fungal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.